নির্দেশনা

Chronic Idiopathic Constipation : Lubiprostone is indicated for the treatment of chronic idiopathic constipation in adults. Opioid-induced Constipation : Lubiprostone is indicated for the treatment of opioid-induced constipation in adults. Irritable Bowel Syndrome with Constipation : Lubiprostone is the only FDA approved drug for the treatment of irritable bowel syndrome with constipation in women >18 years old.

Composition

ফার্মাকোলজি

Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine. By increasing intestinal fluid secretion, Lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with constipation. After administration, Lubiprostone and its metabolites are observed only on the apical (luminal) portion of the gastrointestinal epithelium. Additionally, activation of ClC-2 by Lubiprostone recovers mucosal barrier function via restoration of tight junction protein complexes. Lubiprostone relieves symptoms within 24 hours.

মাত্রা ও সেবনবিধি

Chronic Idiopathic Constipation : Lubiprostone 24 mcg twice daily orally with food and water. Opioid-induced Constipation : Lubiprostone 24 mcg twice daily orally with food and water. Irritable Bowel Syndrome with Constipation : Lubiprostone 8 mcg should be taken twice daily orally with food and water.

প্রতিনির্দেশনা

Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

পার্শ্ব প্রতিক্রিয়া

Nausea, vomiting, loose stools, dry mouth, stomach discomfort, headache, dizziness etc.

গর্ভাবস্থায় ও স্তন্যদানকালে

Pregnancy Category C. Lubiprostone should be used in pregnant mother if the potential benefits justifies the potential risk to the fetus. It is not known whether Lubiprostone is excreted in human milk.

সতর্কতা

Nausea : Patients taking Lubiprostone may experience nausea. If this occurs, concomitant administration of food with Lubiprostone may reduce symptoms of nausea. Diarrhea : Lubiprostone should not be prescribed to patients that have severe diarrhea. Bowel Obstruction : In patients with symptoms suggestive of mechanical gastrointestinal obstruction, confirm the absence of such an obstruction prior to initiating therapy with Lubiprostone.

থেরাপিউটিক ক্লাস

Other laxative preparations

সংরক্ষণ